This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
were compared with the data from 679 patients who were discharged from the hospital with the diagnosis of bronchiolitis after implementation on January 15, 1997. The patients were not given the choice of participating in the study, as the institutional review board concluded that the guideline was primarily a patient care instrument and consent was not required.
Study design
This was a prospective nonrandomised study with historical controls, which was conducted in a single centre. The length of follow-up was not stated. No loss to follow-up was reported.
Analysis of effectiveness
The basis for the analysis of the clinical study (intention to treat or treatment completers only) was not explicitly stated but it appears to have been intention to treat. The outcomes examined were the admission rates, the length of stay, blood gas percentage, and the use of beta2-agonist inhalation, nasopharyngeal wash, X-rays and antibiotics.
There were no significant differences between the ages of the patients between different years. The insurance coverage characteristics for the admitted patients were different before (56% Medicaid/self pay) and after (50% Medicaid/self pay) guideline implementation with significant, but inconsistent, differences in insurance coverage distributions between the years, (p<0.001). There was no significant difference in the distribution of patients when tested by year of admission.
Effectiveness results
The annual number of admission was 325 infants before guideline implementation and 226 after implementation. The difference was 30%, (p<0.001).
The mean length of stay was 2.9 (+/-2) days before guideline implementation and 2.4 (+/-1.5) days after, representing a 17% reduction, (p<0.001).
Sixty-nine per cent of the patients received beta2-agonist inhalation before guideline implementation, compared with 57% after, (p<0.001). The proportion of patients who received more than one dose was 57% before implementation and 41% after, representing a reduction of 28%, (p<0.001).
The use of nasopharyngeal wash to detect respiratory syncytial virus was 89% before guideline implementation and 43% after, representing a 52% reduction, (p<0.002).
X-ray films were ordered in 70% of the patients before guideline implementation and 60% after, representing a 14% reduction, (p<0.001).
The blood gas percentage was the only outcome that increased (by 50%), (p<0.001).
The use of antibiotics was 57% before guideline implementation and 50% after, representing a 12% reduction, (p<0.001).
There was no change in readmissions within 10 days, (p<0.05).
Clinical conclusions
Effectiveness was generally improved after implementation of the guidelines.
Measure of benefits used in the economic analysis
There was no summary measure of benefit. The study therefore constituted a cost-consequences analysis.
NHS Economic Evaluation Database (NHS EED) Produced by the Centre for Reviews and Dissemination Copyright © 2017 University of York
Page: 2 / 5
Direct costs
Discounting was not carried out as the costs were incurred over less than 2 years. The quantities and the costs were analysed separately. The quantities were estimated from actual data. The resources ancillary to bed occupation, length of hospital stay, and all other information used as a basis for generating hospital costs, were obtained retrospectively from the hospital financial and clinical computer systems. Medical records reviews were used selectively to abstract some retrospectively collected data, and also for confirmation as a measure of guideline compliance. The actual cost of each resource used during hospitalisation was extracted on the basis of relative value units. These were computed by the hospital financial system after adjusting all costs to 1999 values for comparability. According to the authors, the cost figures for use of resources ancillary to bed occupancy were easier to define and more reliable. The hospital charges were not included.
Statistical analysis of costs
The data were stratified categorically, based on whether they represented information about care delivered before or after the introduction and implementation of the guideline. Categorical variables were analysed using chi-squared tests, while t-tests were performed for normally distributed continuous variables. Wilcoxon rank sums were used for nonnormally distributed data.
Indirect Costs
The indirect costs were not considered as the study was conducted on the basis of a health service/insurance perspective.
Currency

US dollars ($).
Sensitivity analysis
A sensitivity analysis was not carried out.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
The total mean costs were $3,297 (+/-$2,188) for the period before guideline implementation and $2,825 (+/-$1,898) after implementation, indicating a 14% reduction, (p<0.001).
The mean costs for all ancillary resources were $1,028 (+/-$735) for the period before guideline implementation and $609 (+/-$355) after implementation. The change was 41%, (p<0.001).
The mean costs for the use of respiratory care services alone were $293 (+/-$291) for the period before guideline implementation and $81 (+/-$101) after implementation, indicating a reduction of 72%, (p<0.001).
The respiratory care data set included zero values, thus these costs were tested after transformation to their square roots. The difference was significant, (p<0.001).
Synthesis of costs and benefits
Not relevant.
